Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-ESCAPE feasibility study in advanced inoperable non-mucinous peritoneal malignancy
2005-001875-37Phase 2Unknown
- Sponsor
- University of Warwick
- Start
- Aug 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, paclitaxel and gemcitabine in ovarian cancer, ovarian carcinosarcoma (OCS), fallopian tube cancer (PFTC) and 2 more (2 arms), sponsored by University of Warwick. Primary endpoint: Percentage of patients completing 12 cycles of chemotherapy. Status: unknown.
02
Drugs
carboplatinpaclitaxelgemcitabine
03
Conditions
ovarian cancerovarian carcinosarcoma (OCS)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)peritoneal malignancy (PM)
Beyond the preview
Go deeper on 2005-001875-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001875-37.